Global Liquid Biopsy Market Size was valued nearly USD 23.49 million by 2017 and is estimated to reach up to USD xx.xx million by 2025. According to latest study conducted by our analysts and industry experts, the global market is expected to grow at a CAGR of 14.9% during the forecast period, i.e. 2017-2025. Liquid biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumour through a simple blood sample. Traces of the cancer’s DNA in the blood can give clues about which treatments are most likely to work for that patient. Most cancers have multiple genetic mutations and they may not have the same ones in all parts of the cancer. The tissue samples removed for biopsy may not show all mutations whereas liquid biopsies offer an improved chance of detecting these genetic changes.

Global Market Growth Opportunities (Revenue, Growth) By 2017-2025

This global market study report analysis offers in-depth insights, revenue details, and other vital information regarding the global liquid biopsy market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2025. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global liquid biopsy market report has been segmented on the basis of type, application, and region. It includes the estimation of the market size, in terms of value, with respect to 4 main geographies, namely, North America, Europe, APAC, and RoW.   

Market Dynamics

Liquid Biopsy market estimated to grow at a CAGR of 14.9% between 2018-2025. The market is expected to grow at a significant rate in coming years. The liquid biopsy market is primarily driven by the increasing cases being detected for various types of cancer. Also, considering number of free trails and rising demand for liquid biopsy with minimal invasive surgeries is expected to boost the market growth during forecast period. Additionally, liquid biopsy is the fastest emerging substitute for tissue biopsy due to a smaller number of surgical invasions.

Furthermore, rising number of mergers and acquisitions by the key players owing to the continuous research and development activities is also expected to have positive influence on the growth of liquid biopsy market in the near future.

Segment Analysis 

On the basis of technology type, the global liquid biopsy market is sub-segmented into single gene analysis (PCR Microarrays), and multi-gene-parallel analysis (NGS). NGS multiplex testing helps in diagnosis of multiple diseases at a single time, while PCR are based segmentation helps in analyzing the mutation in the genes. Hence, both technologies are observed to hold similar market shares.

Based on sample type, the global liquid biopsy market is sub-segmented into blood, urine, saliva, and other body fluid. Blood sample is the most common sample type that is used by doctors for proper analysis. Blood contains cell free DNA, circulating cell, and exosomes that can be detected easily, this helps in easy diagnosis of the cancer cell in the human body. Thus, there is an increase in the adoption of liquid biopsy with the help of blood sampling. Moreover, saliva and other body fluids sampling market to be the second largest market owing to the continuous research.

Based on the biomarker type, the global liquid biopsy market is further segmented into exosomes, CTC, and ctDNA. Circulating tumor cells (CTC) is expected to hold the largest market share owing the higher awareness of this technique, and its effective results for tracking cancer cell in the body. In addition, the early detection of the cells helps in appropriate diagnosis and clinical decisions related to cancer in initial stage itself.

Regional Analysis

North America is anticipated to hold the major market share in the global Liquid Biopsy market, owing to favorable reimbursement policies by the local governments, increased government expenditure on developing healthcare infrastructure, and increasing advanced accessibility for the diagnosis of various types of cancer, and increase number of patients suffering from cancer. While Asia Pacific to be the fastest growing market in the coming years. The growth in this region is majorly driven by the rising number of key players in these countries, and the continuous research and development by the Asian countries.

Global Liquid Biopsy Market Size, Share Analysis By Region 2017

Key Players

Major players operating in global Liquid Biopsy market include Roche Diagnostics, Illumina, Inc., Bio-Rad Laboratories Inc., Myriad Genetics, Inc., Menarini Silicon Biosystems, Genomic Health, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Biocept, Inc., Trovagene, Inc., RainDance Technologies, Inc., Guardant Health, Inc., and MDx Health SA.

Global in Liquid Biopsy Market Study Report Offer You!

The global market study report gives an idea about market size, share, stock, equity, investment and total price analysis. Also, the report provides comprehensively industry insights with all major factors such as market credit, allocation, demand, distribution, market scope, key players, end user & applications, provisions, livestock, commodities and industry economics analysis, future growth & forecast. The global market report includes all depth data like pre-market emphasis, market survey, market investment, industry advice, portfolio, finance, access, trade, market exploration, industry review and market predication & projection to develop effective strategies for optimizing their market position.